Daily Anesthesiology Research Analysis
Today’s most impactful anesthesiology research spans perioperative analgesia, team-based systems interventions, and thromboprophylaxis. A double-blind RCT showed that long-acting nalbuphine prodrug (dinalbuphine sebacate) significantly reduced opioid use and improved recovery after VATS. A national stepped-wedge cluster trial modestly improved teamwork in operating rooms, while a PRISMA-compliant meta-analysis clarified when extended aspirin prophylaxis prevents VTE and at what bleeding cost.
Summary
Today’s most impactful anesthesiology research spans perioperative analgesia, team-based systems interventions, and thromboprophylaxis. A double-blind RCT showed that long-acting nalbuphine prodrug (dinalbuphine sebacate) significantly reduced opioid use and improved recovery after VATS. A national stepped-wedge cluster trial modestly improved teamwork in operating rooms, while a PRISMA-compliant meta-analysis clarified when extended aspirin prophylaxis prevents VTE and at what bleeding cost.
Research Themes
- Opioid-sparing multimodal analgesia for thoracic surgery
- Operating room team training and systems safety
- Extended venous thromboembolism prophylaxis trade-offs
Selected Articles
1. Effect of Dinalbuphine sebacate on postoperative multimodal analgesic strategy in video-assisted thoracoscopic surgery: a double-blind randomized controlled trial.
In a double-blind RCT (n=57 analyzed), adding long-acting dinalbuphine sebacate to multimodal analgesia for VATS halved postoperative fentanyl consumption and reduced pain interference and movement pain at 1 week and 1 month. Functional recovery metrics improved without reported safety signals differing between groups.
Impact: Demonstrates clinically meaningful opioid-sparing with improved recovery using a long-acting nalbuphine prodrug within a standardized MMA pathway for thoracic surgery.
Clinical Implications: Consider DS as part of MMA for VATS to reduce opioid requirements and improve early functional outcomes, particularly when regional anesthesia (TPVB) is used. Monitor for typical opioid-related adverse effects and plan for outpatient continuity.
Key Findings
- Three-day fentanyl consumption was markedly lower with DS vs placebo (283 ± 70 µg vs 708 ± 190 µg; P < 0.001).
- Pain interference with daily life was lower at 1 week (28.57% vs 86.2%; P < 0.001) and 1 month (10.71% vs 48.28%; P = 0.003) with DS.
- Movement pain intensity was reduced at 1 week (2.07 ± 0.61 vs 4.00 ± 0.56; P < 0.001) and 1 month (0.64 ± 0.35 vs 2.10 ± 0.4; P < 0.001).
Methodological Strengths
- Double-blind, randomized, placebo-controlled design with trial registration (NCT04962152).
- Standardized MMA including ultrasound-guided TPVB and objective opioid consumption endpoint.
Limitations
- Single-center study with a modest sample size (n=57 analyzed).
- Generalizability limited to VATS with TPVB; safety outcomes not powered for rare events.
Future Directions: Multi-center trials comparing DS against other long-acting analgesic strategies, assessment in opioid-tolerant patients, and cost-effectiveness analyses.
BACKGROUND: Multimodal analgesia (MMA) combines different analgesic methods, such as non-steroidal inflammatory drugs (NSAIDs), acetaminophen, and regional anesthesia techniques, to optimize pain control while minimizing opioid use. Dinalbuphine sebacate (DS), a long-acting prodrug of nalbuphine, was chosen due to its potential to enhance MMA strategies. The aim of this study is to evaluate the effectiveness of DS in MMA for video-assisted thoracoscopic surgery (VATS). METHODS: Sixty participants were randomly and equally assigned to either the MMA regimen containing DS (DS group) or placebo (placebo group). After anesthesia induction, all participants received ultrasound-guided thoracic paravertebral block (TPVB), and DS or placebo was injected into the gluteus medius muscle on the operated side. Intravenous patient-controlled analgesia (IVPCA) with fentanyl was provided for breakthrough pain postoperatively. The primary outcome was postoperative fentanyl consumption over three days. Statistical tests included Student's t-test, chi-square test, and Fisher's exact test.
2. Effects of a national team training intervention for operating theatre teams on patient and staff outcomes: a stepped-wedge cluster-randomised trial and mixed-methods study.
A nationwide stepped-wedge cluster RCT with mixed methods showed modest improvements in observed teamwork after in situ simulation-based training, with 41% staff participation across 19 of 20 boards. Patient outcomes (e.g., DAOH90) could not be clearly attributed to the intervention due to high baseline performance and confounding (including COVID-19).
Impact: One of the largest real-world, national-scale evaluations of OR team training using a robust stepped-wedge design informs systems-level quality and safety efforts.
Clinical Implications: In situ simulation team training can modestly improve teamwork; however, broad patient outcome gains may require higher uptake, sustained implementation, and integration with other safety interventions.
Key Findings
- Nationwide in situ simulation training was implemented in 19/20 boards with 41% staff participation.
- Observed teamwork improved modestly post-intervention.
- Patient outcome improvements (e.g., DAOH90) could not be solely attributed to the intervention due to confounding and high baseline performance.
Methodological Strengths
- Stepped-wedge cluster-randomised design at national scale with mixed-methods evaluation.
- Use of national administrative data and pre-specified outcomes (e.g., DAOH90).
Limitations
- Partial uptake (41%) may have diluted effects; implementation varied across sites.
- Confounding factors (e.g., COVID-19 pandemic) and high baseline performance limited causal attribution for patient outcomes.
Future Directions: Evaluate strategies to increase uptake and sustainment, integrate with checklists and debriefing systems, and test effects on hard clinical outcomes in higher-risk procedures.
BACKGROUND: We evaluated a national, multidisciplinary in situ simulation-based team training intervention in New Zealand public hospitals. We hypothesised that outcomes for surgical patients and staff perceptions of teamwork and observed teamwork behaviours would improve after the intervention. METHODS: In a stepped-wedge cluster trial, all New Zealand's 20 District Health Boards were semi-randomised into four cohorts. Training was progressively implemented with one cohort per year. Patient outcomes were derived from a national administrative dataset. Outcome measures were intervention uptake, days alive and out of hospital at 90 days (DAOH RESULTS: Nineteen District Health Boards implemented training, and 41% of the estimated 3800 eligible staff participated. Post-intervention, DAOH CONCLUSIONS: We achieved small improvements in teamwork by involving 41% of New Zealand operating theatre staff in team training. Improved patient outcomes could not be solely attributed to our intervention, potentially reflecting high baseline levels of teamwork and surgical outcomes, diluting effects of the progressive uptake of the team training over intervention periods, and other confounders including the COVID-19 pandemic. CLINICAL TRIAL REGISTRATION: ACTRN12617000017325.
3. Aspirin for the extended prevention of venous thromboembolism: a meta-analysis and trial sequential analysis.
Across 68,554 participants in 5 RCTs, aspirin (100–160 mg) reduced VTE events, especially in primary prevention and provoked VTE, but increased overall and major bleeding. Low-dose 100 mg did not significantly prevent VTE/DVT/PE, and no benefit was seen in secondary prevention; transfusions and major CV events were unchanged.
Impact: Clarifies when extended aspirin prophylaxis is effective and the associated bleeding cost, informing perioperative and high-risk VTE prevention strategies.
Clinical Implications: Consider aspirin for extended prophylaxis in selected patients at risk of provoked VTE when anticoagulants are unsuitable, while carefully weighing bleeding risks. Low-dose 100 mg may be insufficient; dosing and indication refinement are needed.
Key Findings
- Aspirin (100–160 mg) reduced VTE, DVT, PE, and VTE-related mortality versus placebo, especially in primary prevention and provoked VTE.
- No benefit in secondary prevention; limited benefit for unprovoked VTE confined to overall VTE risk.
- Low-dose aspirin (100 mg) did not significantly reduce VTE/DVT/PE and aspirin increased overall and major bleeding without increasing transfusions or major CV events.
Methodological Strengths
- PRISMA-compliant meta-analysis of RCTs with random-effects modeling and trial sequential analysis.
- Comprehensive subgroup analyses (primary vs secondary prevention; provoked vs unprovoked VTE; dosing).
Limitations
- Heterogeneity across trials and populations; extended prophylaxis contexts varied.
- Dose range limited (100–160 mg); applicability to contemporary prophylaxis alternatives (e.g., DOACs) uncertain.
Future Directions: Head-to-head RCTs versus DOACs for extended prophylaxis, dose-finding for aspirin, and precision risk stratification to balance thrombosis vs bleeding.
Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is a major complication following surgery and in high-risk scenarios. Aspirin may provide an alternative for extended VTE prophylaxis, but its risk-benefit profile remains unclear. We conducted a systematic review and meta-analysis of randomized controlled trials, following PRISMA guidelines, to evaluate aspirin's efficacy and safety for extended VTE prevention. Subgroup analyses included primary and secondary prevention, provoked and unprovoked VTE, and low-dose aspirin. Pooled relative risks (RRs) and 95% confidence intervals (CIs) were calculated using a random-effects model, and trial sequential analysis was used to assess the robustness of the evidence. Five trials including 68,554 patients were analyzed. Aspirin (100-160 mg) significantly reduced the risk of VTE, DVT, PE, and VTE-related mortality compared to placebo, particularly in primary prevention and provoked VTE cases. No benefit was observed in secondary prevention, while some benefit emerged for unprovoked VTE, limited to overall VTE risk. Low-dose aspirin (100 mg) did not significantly reduce the incidence of VTE, DVT, or PE. Aspirin increased the risks of overall and major bleeding but did not elevate blood transfusion requirements or major cardiovascular events. These findings suggest that prolonged aspirin therapy may have a role in extended VTE prevention, particularly in patients at risk for provoked VTE. However, careful patient selection remains crucial, and further studies are needed to refine its indications and optimal dosing strategy.